Related Experiment Video

Updated: Jul 26, 2026

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

Effects of a broad-spectrum behavior modification treatment program on children with refractory epileptic seizures

J Dahl, L Melin, L O Brorson

    Epilepsia
    |July 1, 1985
    PubMed

    Insights

    Behavior modification significantly reduced seizure index in children with refractory epilepsy. This learning-based program offers a promising adjunctive therapy for drug-resistant epilepsy cases.

    Area of Science:

    • Pediatric Neurology
    • Behavioral Science
    • Epilepsy Research

    Background:

    • Refractory epilepsy in children presents significant challenges.
    • Conventional treatments often have limited efficacy for some patients.
    • Behavioral interventions are increasingly explored as complementary therapies.

    Purpose of the Study:

    • To investigate the efficacy of a learning-based behavior modification program.
    • To assess the impact of this program on seizure frequency and duration in children.
    • To evaluate the program's effectiveness as an add-on to standard medical treatment.

    Main Methods:

    • A randomized controlled trial involving 18 children with refractory epilepsy.
    • Three groups: behavior modification, attention control, and a control group.
    • A 'seizure index' (number and duration of seizures) was the primary outcome measure.
    • Data collected over a 10-week baseline, 6-week intervention, and 10-week/1-year follow-ups.

    Main Results:

    • A statistically significant reduction in the seizure index was observed.
    • This reduction was specifically noted in the behavior modification treatment group.
    • The positive effects were sustained at both the 10-week and 1-year follow-ups.

    Conclusions:

    • Behavior modification therapy demonstrates significant effectiveness in reducing seizures.
    • This approach is a valuable potential treatment for children with drug-resistant epilepsy.
    • The findings support the integration of behavioral programs with conventional medical care.

    More Related Videos

    Repeated Transcranial Magnetic Stimulation Combined with Action Observation Training in Children with Spastic Cerebral Palsy07:20

    Repeated Transcranial Magnetic Stimulation Combined with Action Observation Training in Children with Spastic Cerebral Palsy

    Published on: August 9, 2024

    Electromagnetic Source Imaging in Presurgical Evaluation of Children with Drug-Resistant Epilepsy09:57

    Electromagnetic Source Imaging in Presurgical Evaluation of Children with Drug-Resistant Epilepsy

    Published on: September 20, 2024

    Related Concept Videos

    Epilepsy and Seizures: Overview01:24

    Epilepsy and Seizures: Overview

    Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
    Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
    Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

    Antiepileptic Drugs: GABAergic Pathway Potentiators

    γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
    The key GABA pathway potentiators used in epilepsy management are as follows.
    Benzodiazepines are a well-known class of drugs used for their...
    Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

    Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

    Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
    SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
    Behavior Modification01:21

    Behavior Modification

    Behavioral approaches have often been criticized for ignoring mental processes and focusing solely on observable behavior. However, these approaches provide an optimistic perspective for individuals seeking to change their behaviors. Rather than concentrating on intrinsic personality traits, behavioral approaches suggest that even longstanding habits can be modified by changing the reward contingencies that maintain them.
    A real-world application of operant conditioning principles is applied...
    Operant Conditioning Intervention01:24

    Operant Conditioning Intervention

    Operant conditioning serves as a foundational principle in therapeutic interventions aimed at modifying maladaptive behaviors. Central to this approach is the notion that behaviors, both adaptive and maladaptive, are learned through reinforcement. By analyzing the environmental factors that reinforce problematic behaviors, clinicians can design interventions to weaken these reinforcements and replace maladaptive behaviors with healthier alternatives.
    In operant conditioning, behaviors that are...
    Electroconvulsive Therapy01:30

    Electroconvulsive Therapy

    Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early years,...